Prostate Cancer Treatment Options: Surgery, Radiation, Hormone Therapy and More

A diagnosis of prostate cancer does not automatically mean that surgery is required.

Treatment can range from active surveillance for selected low-risk cancers to surgery, radiation therapy, hormone therapy, chemotherapy, targeted treatment or radiopharmaceutical therapy for more advanced disease. Some patients need only one treatment, while others require a combination of treatments.

The right approach depends on several factors, including the stage of prostate cancer, PSA level, Gleason score, Grade Group, MRI findings, whether the cancer has spread, age, overall health, life expectancy and the patient's priorities.

For this reason, there is no single "best prostate cancer treatment" that applies to every patient. This guide sits beside the Prostate Cancer Treatment in India pathway, the treatment-without-surgery guide and the city directories for Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad.

The treatment decision usually starts with one question:

Where is the cancer, and how aggressive is it?

Doctors then combine information from the patient's:

Stage is important, but it is not the only factor.

Two men with the same stage can receive different treatments because their Grade Group, PSA, age, health and personal circumstances may differ. The American Cancer Society also notes that treatment decisions for prostate cancer are influenced by risk group, age, overall health, life expectancy and personal preferences.

A useful way to understand prostate cancer treatment is to divide it into four broad groups.

Used for selected cancers that may not need immediate treatment.

Examples: active surveillance and watchful waiting.

Designed to treat cancer in and around the prostate.

Examples: radical prostatectomy, radiation therapy, brachytherapy and selected focal treatments.

Medicines travel through the body and are used when cancer may be outside the prostate or when systemic treatment is otherwise appropriate.

Examples: hormone therapy, chemotherapy, targeted therapy and selected immunotherapy.

These treatments use radioactive substances linked to molecules that target cancer cells or their environment.

Example: lutetium-177 PSMA therapy in selected advanced prostate cancers, discussed on the India treatment page.

Active surveillance is one of the most important treatment approaches for selected men with low-risk prostate cancer.

It does not mean ignoring the cancer.

Instead, the cancer is monitored closely, with treatment started if there are signs that the disease is becoming more aggressive or clinically significant.

Monitoring may include:

The 2026 EAU guideline recommends active surveillance as standard care for suitable patients with low-risk disease and selected patients with favourable intermediate-risk disease.

The main reason is to avoid unnecessary treatment and its potential side effects when immediate treatment may not provide enough additional benefit.

Surgery and radiation can affect urinary, bowel and sexual function. If a low-risk cancer is unlikely to cause problems for many years, immediate treatment may not always be necessary.

However, active surveillance is a structured medical programme, not simply "doing nothing." There is no single package price; follow-up is billed per visit, PSA test, MRI or biopsy.

Watchful waiting is different from active surveillance.

With active surveillance, the intention is generally to identify disease progression early enough to offer curative treatment if needed.

With watchful waiting, the approach is usually more conservative. It may be appropriate for men whose overall health or life expectancy makes curative treatment less suitable.

Treatment is generally introduced if the cancer causes symptoms or becomes clinically significant.

The EAU distinguishes active surveillance from watchful waiting and considers health status and life expectancy important parts of treatment planning.

Radical prostatectomy is an operation in which the prostate gland is removed.

The seminal vesicles are usually removed as part of the procedure, and nearby lymph nodes may also be removed when indicated.

The objective is to remove the cancer completely when the disease is suitable for curative surgery. The GAF planning range in India is $7,000–$18,000, typically with a 3–7 night stay, covering open, laparoscopic and robotic-assisted approaches.

Radical prostatectomy can be performed through:

The American Cancer Society describes radical prostatectomy as a major surgical treatment for prostate cancer that has not spread beyond the prostate, with the exact surgical approach depending on the clinical situation.

Explore radical prostatectomy — doctors, hospitals and cost in India, including Delhi NCR and Mumbai.

Robotic prostatectomy is a minimally invasive form of radical prostatectomy.

The surgeon controls specialised instruments from a console while operating through small incisions.

The system can provide magnified visualisation, three-dimensional views, articulated instruments and fine control in confined anatomical spaces.

However, the robot does not independently perform the surgery. The surgeon remains responsible for the procedure and makes the operative decisions.

It may be considered for selected men with localised prostate cancer, some locally advanced cancers, and adequate overall health for surgery. The suitability of surgery depends on the tumour's characteristics and the surgeon's assessment.

Patients may experience smaller incisions, less postoperative discomfort, lower blood loss in many cases, shorter hospitalisation and faster initial recovery.

But robotic surgery is not automatically the right treatment for every prostate cancer patient. The cancer stage and risk profile come first.

Related: Robotic Prostatectomy in India and the India treatment pathway.

The nerves involved in erectile function lie close to the prostate.

When the cancer's location allows it, surgeons may try to preserve these nerves during prostatectomy. This is called nerve-sparing surgery.

It may be bilateral, unilateral, partial, or not performed. The decision depends on the likelihood that cancer has extended outside the prostate in the area where the nerves are located.

The priority remains cancer control. Therefore, nerve preservation is considered only when it is oncologically safe.

Some men undergoing radical prostatectomy may also require pelvic lymph node dissection.

During this procedure, selected lymph nodes around the pelvis are removed and examined by a pathologist. The results can help determine whether prostate cancer has spread to the lymph nodes.

This information may influence final staging, risk assessment, postoperative treatment and follow-up. Lymph-node surgery is not required for every prostate cancer patient.

Radiation therapy uses high-energy radiation to damage cancer cells.

It can be used as a curative treatment for selected localised prostate cancers and as part of treatment for higher-risk or locally advanced disease. Radiation can also be used to relieve symptoms caused by metastatic prostate cancer.

Modern radiation treatment can include IMRT, VMAT, IGRT, moderate hypofractionation, SBRT and brachytherapy.

The EAU guideline includes modern image-guided radiation techniques and different fractionation schedules among established treatment approaches for appropriately selected patients. See radiation oncologists in India and radiation hospitals in Delhi NCR.

External-beam radiation therapy delivers radiation from a machine outside the body.

The radiation is carefully planned so that the prostate and areas at risk receive the prescribed dose while surrounding organs are protected as much as possible.

Intensity-modulated radiation therapy uses multiple radiation beams with different intensities. The GAF planning range is $6,500–$14,500.

Volumetric modulated arc therapy delivers radiation while the treatment machine rotates around the patient.

Image-guided radiation therapy uses imaging to improve treatment positioning. The GAF planning range is $7,200–$16,000.

Stereotactic body radiation therapy delivers a highly focused radiation dose over a small number of treatment sessions in selected patients. The GAF planning range is $8,000–$17,500.

The number of treatment sessions depends on the technique and the patient's disease characteristics. Conventional EBRT planning ranges start at $1,000–$6,000+ for about 15–35 sessions.

Brachytherapy is an internal form of radiation therapy.

Instead of delivering radiation from outside the body, a radioactive source is placed in or close to the prostate.

Small radioactive seeds are placed within the prostate.

A radioactive source is temporarily introduced into the prostate and then removed.

Brachytherapy can be used alone in selected patients or combined with external-beam radiation for some higher-risk cancers. The GAF planning range is $5,500–$13,000.

Related: Brachytherapy for Prostate Cancer.

Hormone therapy is also called androgen deprivation therapy (ADT).

Prostate cancer cells can use male hormones called androgens to support their growth. Hormone therapy reduces androgen stimulation.

Depending on the disease setting, hormone treatment may involve LHRH/GnRH agonists, LHRH/GnRH antagonists, androgen-receptor pathway inhibitors or other hormonal approaches.

Medicines such as abiraterone, enzalutamide, apalutamide and darolutamide may be used in appropriate clinical situations.

Hormone therapy can be used with radiation therapy, in locally advanced disease, in metastatic hormone-sensitive prostate cancer, in castration-resistant disease, and as part of combination systemic treatment.

The exact combination and duration depend on the disease stage and previous treatment. The GAF planning range is $1,000–$4,500. See hormone therapy doctors and hospitals.

Because ADT changes hormone levels, it can cause side effects such as:

Long-term hormone treatment therefore requires appropriate monitoring. Bone health is particularly important in men receiving prolonged androgen deprivation.

Chemotherapy uses medicines that circulate throughout the body to attack cancer cells.

Docetaxel is an important chemotherapy drug used in selected advanced prostate cancer settings.

Chemotherapy is particularly relevant when prostate cancer has spread or when systemic treatment is needed.

Modern treatment is increasingly based on combinations rather than viewing chemotherapy in isolation. For example, selected patients with metastatic hormone-sensitive prostate cancer may receive ADT together with an androgen-receptor pathway inhibitor and, in appropriate cases, chemotherapy. The 2026 EAU guideline includes updated recommendations for systemic treatment combinations in metastatic disease.

The GAF planning range is $1,500–$8,000+, usually as outpatient cycles. See chemotherapy doctors.

Targeted therapy works against specific molecular characteristics of cancer.

This is particularly important in advanced prostate cancer because genetic testing can identify alterations that may open additional treatment options.

Some prostate cancers have abnormalities involving DNA-repair genes such as BRCA1, BRCA2, ATM and other homologous recombination repair genes.

PARP inhibitors are an example of targeted treatment used in selected patients with relevant molecular alterations.

The important point is that targeted therapy is not automatically appropriate simply because prostate cancer is advanced. The tumour's molecular profile matters. The GAF planning range is $8,000–$30,000.

Immunotherapy uses the body's immune system to recognise and attack cancer cells.

Its role in prostate cancer is more selective than in some other cancers.

It may be considered for specific patients based on tumour characteristics, previous treatment and eligibility criteria.

Patients should therefore not assume that an immunotherapy used successfully for another cancer will necessarily work for prostate cancer. Where used, the GAF planning range for immunotherapy is $15,000–$45,000.

PSMA stands for prostate-specific membrane antigen. Many prostate cancer cells express PSMA on their surface. This characteristic can be used for both imaging and treatment.

A PSMA-targeting tracer is injected into the body and detected using PET imaging. It can help identify prostate cancer deposits in selected staging and recurrence situations.

A radioactive isotope can be attached to a PSMA-targeting molecule. One example is lutetium-177 PSMA therapy.

The targeting molecule carries the radioactive substance toward PSMA-expressing cancer cells, allowing radiation to be delivered more directly to those cells.

This treatment is primarily relevant to selected patients with advanced disease and requires specialist assessment. The 2026 EAU guidelines specifically include updated recommendations around imaging and systemic treatment for advanced prostate cancer.

Related: Lutetium-177 PSMA Therapy in India.

Focal treatments aim to destroy the cancerous area while leaving much of the prostate untreated.

Examples include high-intensity focused ultrasound (HIFU), cryotherapy and other ablative approaches.

These treatments can sound attractive because they appear to offer a middle ground between surveillance and complete prostate removal. However, they are not appropriate for every patient.

Current EAU guidance is cautious about focal and whole-gland ablative approaches and recommends their use only in specific circumstances, including clinical trials or registries for some applications.

Patients should therefore ask about the quality of long-term evidence before choosing focal treatment.

For suitable patients, active surveillance is often the preferred approach.

Other possible treatments may include radical prostatectomy, radiation therapy and brachytherapy in selected cases. The choice depends on factors such as life expectancy, tumour characteristics and patient preferences.

Intermediate-risk disease is not one uniform category. Doctors often distinguish between favourable intermediate risk and unfavourable intermediate risk.

Depending on the patient's exact disease, treatment may include active surveillance in selected favourable cases, radical prostatectomy, external-beam radiation, brachytherapy, or radiation combined with short-term hormone therapy.

The EAU and other major cancer organisations emphasise risk stratification rather than treating every intermediate-risk cancer in exactly the same way.

High-risk prostate cancer has a greater likelihood of recurrence and progression. Treatment often involves more than one modality.

Potential approaches include radical prostatectomy in selected patients, external-beam radiation plus long-term hormone therapy, radiation plus brachytherapy in selected patients, and additional systemic treatment in specific high-risk settings.

The EAU 2026 guideline includes long-term ADT with radiation and additional systemic approaches for selected high-risk patients.

Locally advanced prostate cancer has extended outside the prostate or involves nearby structures and/or regional lymph nodes, depending on the specific stage.

Treatment may involve radiation therapy, long-term hormone therapy, additional systemic treatment, and surgery in carefully selected patients. The exact approach depends on the pattern and extent of local spread.

Metastatic prostate cancer has spread to distant parts of the body. The bones and distant lymph nodes are common sites of spread, although other organs can also be involved.

At this stage, treatment usually focuses on controlling cancer throughout the body.

Options can include androgen deprivation therapy, androgen-receptor pathway inhibitors, chemotherapy, targeted therapy, radiopharmaceutical therapy, radiation to selected sites, bone-directed treatment and clinical trials.

For many men, metastatic prostate cancer is treatable but not considered curable with currently available standard treatments. The goal may be to control the disease, delay progression, relieve symptoms and maintain quality of life.

This table is a simplified overview. Actual treatment decisions depend on the TNM stage, PSA, Grade Group, imaging, health status and life expectancy.

One of the most common questions after diagnosis is:

"Should I have surgery or radiation?"

There is no universal answer. For some men with localised disease, both can be appropriate curative treatments.

The decision can depend on cancer risk, tumour location, age, life expectancy, urinary symptoms, baseline sexual function, other health conditions, patient priorities and local expertise.

The American Cancer Society notes that men with early prostate cancer can have several reasonable treatment options, and the choice involves balancing cancer control against potential treatment effects and personal priorities.

Neither column represents a recommendation. The appropriate treatment depends on the patient's clinical situation.

Yes. Surgery is not required for every prostate cancer patient.

Depending on the disease, alternatives may include:

The important question is not simply "Can I avoid surgery?" It is: which treatment gives appropriate cancer control while fitting my disease, health and priorities?

It depends on the stage and biology of the cancer.

For many men with localised prostate cancer, treatment is given with curative intent.

For metastatic prostate cancer, treatment generally aims to control the disease rather than eradicate every cancer cell.

A patient's prognosis cannot be determined from the word "prostate cancer" alone. Doctors need to consider stage, PSA, Grade Group, Gleason score, tumour volume, lymph-node involvement, metastases and response to treatment.

Treatment does not necessarily mark the end of the cancer journey. Follow-up is important after surgery, radiation and systemic treatment.

PSA is one of the most important follow-up tests. After radical prostatectomy, PSA is expected to fall to a very low level. After radiation, PSA behaves differently and can take time to reach its lowest level.

Doctors may also monitor urinary function, sexual function, bowel symptoms, hormone-treatment effects, bone health and imaging findings when indicated.

The EAU describes follow-up as an important part of assessing cancer control, treatment compliance, side effects, functional outcomes and the need for additional treatment.

Recurrence does not mean that there are no further treatment options.

The next step depends on where the recurrence is located and what treatment the patient received initially.

Doctors may assess PSA, PSA doubling time, MRI, PSMA PET/CT, other imaging, previous pathology, and previous radiation or surgery.

Possible treatments can include salvage radiation, hormone therapy, systemic therapy, selected surgery, targeted therapy and PSMA-targeted radiopharmaceutical treatment.

The treatment pathway for recurrence is different from the initial treatment pathway and should be planned by a specialist team.

The side effects depend on the treatment.

Possible effects vary according to the drug but can include fatigue, nausea, lower blood-cell counts, infection risk, hair loss and peripheral neuropathy with some drugs.

Patients should discuss the expected side effects of their specific treatment rather than assuming that every side effect will occur.

This is an important part of prostate cancer treatment.

A treatment decision is not based only on removing or destroying cancer. Doctors also consider what treatment may mean for urinary control, sexual function, bowel function, physical independence, daily activities, long-term health and emotional wellbeing.

This is particularly important in localised prostate cancer, where several treatment options may be available.

A younger, otherwise healthy man with a long life expectancy may approach the decision differently from an older man with significant medical conditions.

The EAU specifically recommends incorporating health status, comorbidities and life expectancy into prostate cancer management.

Prostate cancer can involve several specialties. Depending on the disease, the treatment team may include a uro-oncologist, urologist, radiation oncologist, medical oncologist, radiologist, pathologist, nuclear medicine specialist, oncology nurse and rehabilitation specialists.

A multidisciplinary review can be particularly useful when the cancer is high-risk, surgery and radiation are both possible, the cancer has spread or returned, multiple treatment options are being considered, or advanced systemic treatment is required.

India has tertiary cancer centres offering a broad range of prostate cancer services, including uro-oncology, robotic-assisted prostate surgery, radiation oncology, brachytherapy, medical oncology, advanced imaging, PSMA PET/CT and selected radiopharmaceutical treatments.

For an international patient, the most useful approach is to choose the treatment centre based on the clinical requirement, rather than simply selecting a hospital because it is well known.

For example, a patient being evaluated for robotic prostatectomy may need a centre with experienced uro-oncology surgeons in Delhi NCR or Mumbai, while a patient with metastatic disease may need a centre with medical oncology, molecular testing, nuclear medicine and radiopharmaceutical capabilities in Bengaluru, Chennai or Hyderabad.

Related: Prostate Cancer Treatment in India.

There is no single cost for prostate cancer treatment.

The total expense depends on the type of treatment, cancer stage, hospital, city, surgical approach, robotic technology, radiation technique, number of treatment sessions, medicines, hospital stay, diagnostic investigations, follow-up and treatment complications.

Current GAF planning ranges include radical prostatectomy $7,000–$18,000, EBRT $1,000–$6,000+, IMRT $6,500–$14,500, brachytherapy $5,500–$13,000, hormone therapy $1,000–$4,500 and chemotherapy $1,500–$8,000+. These are planning ranges, not hospital quotations.

For international patients, the total budget may also include accommodation, flights, local transportation, medical visa expenses, attendant expenses and additional stay.

A personalised hospital quotation is therefore more useful than relying on a generic online price.

Related: Prostate Cancer Treatment Cost in India.

International patients can often make the process easier by collecting their medical records before travelling.

Important documents include:

A specialist can then review the records and determine whether additional testing is needed. This can reduce unnecessary duplication of investigations after arrival.

Before making a treatment decision, consider asking:

There is no single treatment used for every patient. Treatment depends on the cancer's risk group and stage. Active surveillance, surgery and radiation are important options for selected localised cancers, while systemic treatments become increasingly important in advanced disease.

No. Some low-risk cancers can be managed with active surveillance, while radiation and other treatments may be appropriate for selected patients.

They are different treatment approaches and are suitable for different clinical situations. For selected localised cancers, both surgery and radiation can be used with curative intent. The decision should consider cancer risk, health, life expectancy and potential side effects.

Yes. Treatment options can include active surveillance, radiation therapy, brachytherapy and, in selected advanced cases, systemic treatment.

Treatment generally involves systemic therapy. Depending on the disease, this may include ADT, androgen-receptor pathway inhibitors, chemotherapy, targeted therapy and selected radiopharmaceutical treatments.

Hormone therapy reduces androgen stimulation of prostate cancer cells. It may be used alone in selected circumstances or combined with radiation and other systemic treatments.

PSMA-targeted radiopharmaceutical therapy uses a molecule that targets PSMA-expressing prostate cancer cells and carries a radioactive substance to them.

HIFU and other focal treatments may be considered in selected circumstances, but they are not established as a universal replacement for surgery or radiation. Current EAU guidance recommends caution and restricts some focal treatment approaches to clinical trials or registries.

Yes. Some patients experience biochemical or clinical recurrence after treatment. PSA monitoring and appropriate imaging help identify recurrence and guide further treatment.

It depends on the treatment. Surgery is generally completed during a hospital admission, while radiation can involve multiple treatment sessions. Hormone therapy and systemic treatment may continue for months or longer.

A second opinion can be particularly useful when major treatment choices are involved, such as deciding between surgery and radiation or planning treatment for high-risk, recurrent or metastatic disease. A second opinion is more useful when the specialist can review the actual pathology and imaging rather than only a written diagnosis.

Prostate cancer treatment is highly individualised.

A low-risk cancer may require careful monitoring rather than immediate treatment. A localised cancer may be treated with surgery or radiation. Higher-risk disease may require combined treatment, while metastatic prostate cancer often requires long-term systemic therapy.

The most important information for deciding treatment is:

PSA + Gleason score/Grade Group + stage + imaging + overall health + life expectancy + treatment priorities.

If you have recently received a prostate cancer diagnosis, the next useful step is usually not to choose a treatment based on a single online article. It is to have your PSA, biopsy, pathology and imaging reviewed by an appropriate prostate cancer specialist and discuss the benefits and risks of the available options.

GAF Healthcare coordinates international patients who want prostate cancer treatment in India. Share PSA reports, biopsy and Grade Group, MRI or PSMA PET, and previous treatment records. A coordinator can arrange specialist review, an itemized estimate and travel planning. The treating uro-oncology, radiation or medical oncology team makes the final recommendation.

This article is intended for educational purposes and does not replace medical advice from a qualified urologist, uro-oncologist, radiation oncologist or medical oncologist.

Treatment recommendations can differ according to the patient's pathology, stage, imaging, health status, previous treatment and individual circumstances.

1. European Association of Urology — Prostate Cancer Guidelines 2026 — active surveillance, surgery, radiation, systemic treatment, metastatic disease and follow-up.

2. National Cancer Institute — Prostate Cancer Treatment (PDQ) — surgery, radiation, hormone therapy, chemotherapy, targeted therapy and other treatments.

3. American Cancer Society — Prostate Cancer Treatment by Stage — how options vary by stage, risk group, PSA, Grade Group, health and circumstances.

4. American Cancer Society — Treating Prostate Cancer — surveillance, surgery, radiation, hormone therapy, chemotherapy, immunotherapy, targeted therapy and metastatic disease.

5. American Cancer Society — Prostate Cancer Staging — how PSA, Grade Group, tumour extent, lymph nodes and metastases contribute to staging.

Last reviewed against the cited sources: September 2026.